Biotika Past Earnings Performance
Past criteria checks 2/6
Biotika's earnings have been declining at an average annual rate of -44%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 25.2% per year. Biotika's return on equity is 1.4%, and it has net margins of 2.3%.
Key information
-44.0%
Earnings growth rate
-46.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -25.2% |
| Return on equity | 1.4% |
| Net Margin | 2.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Biotika makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16 | 0 | 0 | 0 |
| 31 Dec 22 | 11 | -1 | 0 | 0 |
| 30 Sep 22 | 10 | -1 | 0 | 0 |
| 30 Jun 22 | 9 | -1 | 0 | 0 |
| 31 Mar 22 | 9 | 0 | 0 | 0 |
| 31 Dec 21 | 9 | 0 | 0 | 0 |
| 30 Jun 21 | 12 | 1 | 0 | 0 |
| 31 Mar 21 | 15 | 2 | 0 | 0 |
| 31 Dec 20 | 18 | 2 | 0 | 0 |
| 30 Jun 20 | 26 | 3 | 0 | 0 |
| 31 Mar 20 | 26 | 2 | 0 | 0 |
| 31 Dec 19 | 26 | 2 | 0 | 0 |
| 30 Sep 19 | 27 | 2 | 3 | 0 |
| 30 Jun 19 | 28 | 2 | 6 | 0 |
| 31 Mar 19 | 29 | 2 | 6 | 0 |
| 31 Dec 18 | 30 | 1 | 6 | 0 |
| 30 Sep 18 | 29 | 2 | 6 | 0 |
| 30 Jun 18 | 27 | 3 | 6 | 0 |
| 31 Mar 18 | 27 | 3 | 6 | 0 |
| 31 Dec 17 | 27 | 3 | 6 | 0 |
| 30 Sep 17 | 28 | 2 | 6 | 0 |
| 30 Jun 17 | 29 | 1 | 6 | 0 |
| 31 Mar 17 | 28 | 1 | 6 | 0 |
| 31 Dec 16 | 28 | 1 | 6 | 0 |
| 30 Sep 16 | 35 | 2 | 6 | 0 |
| 30 Jun 16 | 41 | 2 | 7 | 0 |
| 31 Mar 16 | 49 | 3 | 7 | 0 |
| 31 Dec 15 | 58 | 4 | 7 | 0 |
| 30 Sep 15 | 57 | 4 | 7 | 0 |
| 30 Jun 15 | 56 | 5 | 7 | 0 |
| 31 Mar 15 | 54 | 4 | 7 | 0 |
| 31 Dec 14 | 52 | 3 | 7 | 0 |
Quality Earnings: 1BSL01AE has high quality earnings.
Growing Profit Margin: 1BSL01AE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1BSL01AE's earnings have declined by 44% per year over the past 5 years.
Accelerating Growth: 1BSL01AE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 1BSL01AE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 1BSL01AE's Return on Equity (1.4%) is considered low.